Recursion Pharmaceuticals (RXRX)
(Real Time Quote from BATS)
$6.72 USD
-0.08 (-1.18%)
Updated Sep 23, 2024 03:44 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Income Statements
Fiscal Year end for Recursion Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 45 | 40 | 10 | 4 | 2 |
Cost Of Goods | 43 | 48 | 0 | 0 | 0 |
Gross Profit | 2 | -8 | 10 | 4 | 2 |
Selling & Adminstrative & Depr. & Amort Expenses | 352 | 237 | 193 | 89 | 65 |
Income After Depreciation & Amortization | -350 | -246 | -183 | -85 | -62 |
Non-Operating Income | 18 | 6 | -4 | -2 | 1 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -332 | -239 | -186 | -87 | -62 |
Income Taxes | -4 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -328 | -239 | -186 | -87 | -62 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -328 | -239 | -186 | -87 | -62 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -326 | -234 | -174 | -81 | -59 |
Depreciation & Amortization (Cash Flow) | 24 | 12 | 8 | 4 | 3 |
Income After Depreciation & Amortization | -350 | -246 | -183 | -85 | -62 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 207.85 | 175.54 | 125.35 | NA | NA |
Diluted EPS Before Non-Recurring Items | -1.58 | -1.36 | -1.49 | NA | NA |
Diluted Net EPS (GAAP) | -1.58 | -1.36 | -1.49 | -3.99 | NA |
Fiscal Year end for Recursion Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 14.42 | 13.79 | 10.89 | 10.53 | 11.02 |
Cost Of Goods | 9.20 | 11.17 | 9.88 | 10.88 | 9.38 |
Gross Profit | 5.22 | 2.63 | 1.01 | -0.34 | 1.64 |
SG&A, R&D, and Dept/Amort Expenses | 105.76 | 98.97 | 99.94 | 99.21 | 83.35 |
Income After SG&A, R&D, and Dept/Amort Expenses | -100.54 | -96.34 | -98.93 | -99.55 | -81.71 |
Non-Operating Income | 2.48 | 4.19 | 1.87 | 6.53 | 4.99 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -98.06 | -92.15 | -97.06 | -93.02 | -76.73 |
Income Taxes | -0.52 | -0.78 | -4.06 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -97.54 | -91.37 | -93.00 | -93.02 | -76.73 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -97.54 | -91.37 | -93.00 | -93.02 | -76.73 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 242.20 | 236.02 | 233.16 | 214.33 | 201.42 |
Diluted EPS Before Non-Recurring Items | -0.40 | -0.39 | -0.40 | -0.43 | -0.38 |
Diluted Net EPS (GAAP) | -0.40 | -0.39 | -0.43 | -0.43 | -0.38 |